317 related articles for article (PubMed ID: 28382493)
1. Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.
Larivée N; Suissa S; Coulombe J; Tagalakis V; Filion KB
Drug Saf; 2017 Jul; 40(7):583-596. PubMed ID: 28382493
[TBL] [Abstract][Full Text] [Related]
2. Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study.
Larivée N; Suissa S; Eberg M; Joseph L; Eisenberg MJ; Abenhaim HA; Filion KB
BJOG; 2017 Oct; 124(11):1672-1679. PubMed ID: 27704723
[TBL] [Abstract][Full Text] [Related]
3. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
Bird ST; Delaney JA; Etminan M; Brophy JM; Hartzema AG
J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
[TBL] [Abstract][Full Text] [Related]
4. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
5. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
Jick SS; Hernandez RK
BMJ; 2011 Apr; 342():d2151. PubMed ID: 21511805
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
Parkin L; Sharples K; Hernandez RK; Jick SS
BMJ; 2011 Apr; 342():d2139. PubMed ID: 21511804
[TBL] [Abstract][Full Text] [Related]
7. Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies.
Larivée N; Suissa S; Khosrow-Khavar F; Tagalakis V; Filion KB
BJOG; 2017 Sep; 124(10):1490-1499. PubMed ID: 28276140
[TBL] [Abstract][Full Text] [Related]
8. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
Sehovic N; Smith KP
Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
Dinger J; Bardenheuer K; Heinemann K
Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
Dinger J; Möhner S; Heinemann K
Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
[TBL] [Abstract][Full Text] [Related]
11. Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta-analysis.
Bateson D; Butcher BE; Donovan C; Farrell L; Kovacs G; Mezzini T; Raynes-Greenow C; Pecoraro G; Read C; Baber R
Aust Fam Physician; 2016; 45(1):59-64. PubMed ID: 27051991
[TBL] [Abstract][Full Text] [Related]
12. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data.
Schink T; Princk C; Braitmaier M; Haug U
BJOG; 2022 Dec; 129(13):2107-2116. PubMed ID: 35876787
[TBL] [Abstract][Full Text] [Related]
13. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
Tepper NK; Dragoman MV; Gaffield ME; Curtis KM
Contraception; 2017 Feb; 95(2):130-139. PubMed ID: 27771476
[TBL] [Abstract][Full Text] [Related]
14. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database.
Li J; Panucci G; Moeny D; Liu W; Maro JC; Toh S; Huang TY
JAMA Intern Med; 2018 Nov; 178(11):1482-1488. PubMed ID: 30285041
[TBL] [Abstract][Full Text] [Related]
15. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.
Heinemann K; Heinemann LA
J Fam Plann Reprod Health Care; 2011 Jul; 37(3):132-5. PubMed ID: 21659330
[No Abstract] [Full Text] [Related]
16. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
Lidegaard Ø; Nielsen LH; Skovlund CW; Skjeldestad FE; Løkkegaard E
BMJ; 2011 Oct; 343():d6423. PubMed ID: 22027398
[TBL] [Abstract][Full Text] [Related]
17. Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review.
Wu CQ; Grandi SM; Filion KB; Abenhaim HA; Joseph L; Eisenberg MJ
BJOG; 2013 Jun; 120(7):801-10. PubMed ID: 23530659
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic risks of oral contraceptives.
Rott H
Curr Opin Obstet Gynecol; 2012 Aug; 24(4):235-40. PubMed ID: 22729096
[TBL] [Abstract][Full Text] [Related]
19. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
20. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
Dinger J; Do Minh T; Heinemann K
Contraception; 2016 Oct; 94(4):328-39. PubMed ID: 27343748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
